{"id":534056,"date":"2023-03-10T00:00:00","date_gmt":"2023-03-10T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/epidim0035-biopharma-chronic-urticaria-epidemiology-mature-markets\/"},"modified":"2026-04-17T05:19:02","modified_gmt":"2026-04-17T05:19:02","slug":"epidim0035-biopharma-chronic-urticaria-epidemiology-mature-markets","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/epidim0035-biopharma-chronic-urticaria-epidemiology-mature-markets\/","title":{"rendered":"Chronic Urticaria &#8211; Epidemiology &#8211; Mature Markets"},"content":{"rendered":"<p>Clarivate Epidemiology\u2019s coverage of chronic urticaria (<abbr data-abbreviation-entity=\"10048\" title=\"chronic urticaria\">CU<\/abbr>) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report the prevalence of <abbr data-abbreviation-entity=\"10048\" title=\"chronic urticaria\">CU<\/abbr> for each country, as well as annualized case counts projected to the national population.<\/p>\n<p>Most patient populations are forecast over a period of 20 years for the mature pharmaceutical markets of the United States, Europe, and Japan.<\/p>\n<p>Clarivate Epidemiology\u2019s <abbr data-abbreviation-entity=\"10048\" title=\"chronic urticaria\">CU<\/abbr> forecast will answer the following questions:<\/p>\n<ul class=\"round-bullets\">\n<li>Of all people with <abbr data-abbreviation-entity=\"10048\" title=\"chronic urticaria\">CU<\/abbr>, how many in each of the major mature pharmaceutical markets have been formally diagnosed?<\/li>\n<li>Of all people diagnosed with <abbr data-abbreviation-entity=\"10048\" title=\"chronic urticaria\">CU<\/abbr>, how many in each developed country are drug-treated?<\/li>\n<li>How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of <abbr data-abbreviation-entity=\"10048\" title=\"chronic urticaria\">CU<\/abbr> over the forecast period?<\/li>\n<\/ul>\n<p>All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.<\/p>\n<p>Clarivate Epidemiology forecasts the following <abbr data-abbreviation-entity=\"10048\" title=\"chronic urticaria\">CU<\/abbr> patient populations:<\/p>\n<ul class=\"round-bullets\">\n<li>Diagnosed 12-month prevalent cases of <abbr data-abbreviation-entity=\"10048\" title=\"chronic urticaria\">CU<\/abbr>.<\/li>\n<li>Total 12-month prevalent cases of spontaneous <abbr data-abbreviation-entity=\"10048\" title=\"chronic urticaria\">CU<\/abbr>.<\/li>\n<li>Total 12-month prevalent cases of inducible <abbr data-abbreviation-entity=\"10048\" title=\"chronic urticaria\">CU<\/abbr>.<\/li>\n<li>Total 12-month prevalent cases of spontaneous and inducible (overlap) <abbr data-abbreviation-entity=\"10048\" title=\"chronic urticaria\">CU<\/abbr>.<\/li>\n<li>Diagnosed 12-month prevalent cases of spontaneous <abbr data-abbreviation-entity=\"10048\" title=\"chronic urticaria\">CU<\/abbr>.<\/li>\n<li>Undiagnosed 12-month prevalent cases of spontaneous <abbr data-abbreviation-entity=\"10048\" title=\"chronic urticaria\">CU<\/abbr>.<\/li>\n<li>Diagnosed 12-month prevalent cases of inducible <abbr data-abbreviation-entity=\"10048\" title=\"chronic urticaria\">CU<\/abbr>.<\/li>\n<li>Undiagnosed 12-month prevalent cases of inducible <abbr data-abbreviation-entity=\"10048\" title=\"chronic urticaria\">CU<\/abbr>.<\/li>\n<li>Diagnosed 12-month prevalent cases of spontaneous and inducible (overlap) <abbr data-abbreviation-entity=\"10048\" title=\"chronic urticaria\">CU<\/abbr>.<\/li>\n<li>Undiagnosed 12-month prevalent cases of spontaneous and inducible (overlap) <abbr data-abbreviation-entity=\"10048\" title=\"chronic urticaria\">CU<\/abbr>.<\/li>\n<li>Diagnosed drug-treated prevalent cases of spontaneous <abbr data-abbreviation-entity=\"10048\" title=\"chronic urticaria\">CU<\/abbr>.<\/li>\n<li>Diagnosed non-drug-treated prevalent cases of spontaneous <abbr data-abbreviation-entity=\"10048\" title=\"chronic urticaria\">CU<\/abbr>.<\/li>\n<li>Diagnosed drug-treated prevalent cases of inducible <abbr data-abbreviation-entity=\"10048\" title=\"chronic urticaria\">CU<\/abbr>.<\/li>\n<li>Diagnosed non-drug-treated prevalent cases of inducible <abbr data-abbreviation-entity=\"10048\" title=\"chronic urticaria\">CU<\/abbr>.<\/li>\n<\/ul>\n<p>Note: Coverage may vary by country.<\/p>\n","protected":false},"template":"","class_list":["post-534056","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-urticaria","biopharma-product-epidemiology","biopharma-date-975"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/534056","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/534056\/revisions"}],"predecessor-version":[{"id":534310,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/534056\/revisions\/534310"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=534056"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}